SCHEMBL4787011

SCHEMBL4787011

Cc1ccc(NC(=O)Nc2ccc(-c3ccc(C)c4noc(N)c34)cc2)cc1F

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDR P35968 18/20 0.66
▸ KIT P10721 10/20 0.66
▸ FLT3 P36888 19/20 0.59
▸ FLT1 P17948 4/20 0.59
▸ LCK P06239 3/20 0.59
▸ FYN P06241 3/20 0.59
▸ LYN P07948 3/20 0.59
▸ SRC P12931 3/20 0.59
▸ FLT4 P35916 3/20 0.59
▸ BLK P51451 3/20 0.59
▸ CSF1R P07333 3/20 0.59
▸ AURKA O14965 2/20 0.59
▸ DYRK3 O43781 2/20 0.59
▸ ROCK2 O75116 2/20 0.59
▸ RPS6KA5 O75582 2/20 0.59
▸ PRKD3 O94806 2/20 0.59
▸ MAP4K4 O95819 2/20 0.59
▸ NTRK1 P04629 2/20 0.59
▸ RET P07949 2/20 0.59
▸ FGFR1 P11362 2/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4739508 0.89 KDR (0.63) KDRKITFLT3FLT1LCK
SCHEMBL4735877 0.88 FLT3 (0.58) KDRKITFLT3FLT1LCK
SCHEMBL4740470 0.87 KDR (0.76) KDRKITFLT3FLT1LCK
SCHEMBL1379853 0.87 KDR (0.61) KDRKITFLT3FLT1LCK
SCHEMBL1380780 0.87 FLT3 (0.58) KDRKITFLT3FLT1LCK
SCHEMBL4739605 0.86 KDR (0.67) KDRKITFLT3FLT1LCK
SCHEMBL4740182 0.85 KDR (0.72) KDRKITFLT3FLT1LCK
SCHEMBL1384184 0.85 KDR (0.59) KDRKITFLT3FLT1LCK
SCHEMBL425367 0.85 KDR (0.77) KDRKITFLT3FLT1LCK
SCHEMBL4735746 0.85 KDR (0.68) KDRKITFLT3FLT1LCK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2008080110-A1 METHODS FOR TREATING MACULAR EDEMA AND PATHOLOGIC OCULAR ANGIOGENESIS USING A NEUROPROTECTIVE AGENT AND A RECEPTOR TYROSINE KINASE INHIBITOR ALCON, INC. (CH) 2008-07-03 — — WO claimed
EP-1850839-A2 METHODS FOR TREATING OCULAR ANGIOGENESIS, RETINAL EDEMA, RETINAL ISCHEMIA, AND DIABETIC RETINOPATHY USING SELECTIVE RTK INHIBITORS ALCON INC. (CH) 2007-11-07 — — EP claimed
WO-2006091801-A2 METHODS FOR TREATING OCULAR ANGIOGENESIS, RETINAL EDEMA, RETINAL ISCHEMIA, AND DIABETIC RETINOPATHY USING SELECTIVE RTK INHIBITORS ALCON, INC. (CH) 2006-08-31 — — WO claimed
Send feedback